Equities analysts expect that Gilead Sciences, Inc. (NASDAQ:GILD) will post $5.74 billion in sales for the current quarter, according to Zacks. Eight analysts have made estimates for Gilead Sciences’ earnings, with the lowest sales estimate coming in at $5.27 billion and the highest estimate coming in at $6.05 billion. Gilead Sciences posted sales of $7.32 billion during the same quarter last year, which would indicate a negative year-over-year growth rate of 21.6%. The company is scheduled to announce its next quarterly earnings report after the market closes on Tuesday, February 6th.

According to Zacks, analysts expect that Gilead Sciences will report full-year sales of $5.74 billion for the current year, with estimates ranging from $25.42 billion to $26.21 billion. For the next year, analysts anticipate that the firm will post sales of $22.00 billion per share, with estimates ranging from $19.77 billion to $23.47 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that cover Gilead Sciences.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. During the same quarter in the previous year, the business earned $2.75 EPS. Gilead Sciences’s quarterly revenue was down 13.2% compared to the same quarter last year.

A number of research analysts have weighed in on the stock. BidaskClub raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday. Wells Fargo & Co raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $79.02 to $96.00 in a research report on Tuesday. Mizuho reissued a “buy” rating on shares of Gilead Sciences in a research report on Friday, September 29th. Vetr lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 target price for the company. in a research report on Wednesday. Finally, BMO Capital Markets reissued a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, January 3rd. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eighteen have assigned a buy rating to the company’s stock. Gilead Sciences has a consensus rating of “Buy” and a consensus price target of $85.53.

Shares of Gilead Sciences (NASDAQ GILD) opened at $81.74 on Thursday. The stock has a market cap of $106,750.00, a price-to-earnings ratio of 9.30, a P/E/G ratio of -1.71 and a beta of 1.13. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. Gilead Sciences has a 52 week low of $63.76 and a 52 week high of $86.27.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 28th. Stockholders of record on Friday, December 15th were given a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.54%. The ex-dividend date of this dividend was Thursday, December 14th. Gilead Sciences’s dividend payout ratio is currently 23.66%.

In other news, EVP Gregg H. Alton sold 30,000 shares of the company’s stock in a transaction dated Thursday, January 11th. The shares were sold at an average price of $79.00, for a total transaction of $2,370,000.00. Following the completion of the transaction, the executive vice president now owns 57,114 shares of the company’s stock, valued at $4,512,006. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the transaction, the executive vice president now directly owns 77,363 shares of the company’s stock, valued at approximately $5,788,299.66. The disclosure for this sale can be found here. Insiders have sold 491,666 shares of company stock valued at $36,442,567 in the last ninety days. 1.30% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. increased its stake in Gilead Sciences by 1.9% in the second quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock valued at $7,425,281,000 after acquiring an additional 1,937,031 shares during the period. Vanguard Group Inc. increased its stake in Gilead Sciences by 2.4% in the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after acquiring an additional 2,148,697 shares during the period. Bank of New York Mellon Corp increased its stake in Gilead Sciences by 1.0% in the second quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock valued at $2,185,784,000 after acquiring an additional 310,607 shares during the period. FMR LLC increased its stake in Gilead Sciences by 1.1% in the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock valued at $1,630,581,000 after acquiring an additional 258,005 shares during the period. Finally, Northern Trust Corp increased its stake in Gilead Sciences by 0.7% in the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock valued at $1,162,949,000 after acquiring an additional 116,780 shares during the period. 75.95% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This news story was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/18/zacks-analysts-anticipate-gilead-sciences-inc-gild-will-announce-quarterly-sales-of-5-74-billion.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Get a free copy of the Zacks research report on Gilead Sciences (GILD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.